The following listing is found in the FDA Orange Book:  Act…

The following listing is found in the FDA Orange Book:  Active Ingredient: EZETIMIBE Proprietary Name: EZETIMIBE Dosage Form; Route of Administration: TABLET; ORAL Strength: 10MG Reference Listed Drug: No Reference Standard: No TE Code: AB Application Number: A209838 Product Number: 001 Approval Date: Aug 25, 2017 Applicant Holder Full Name: AUROBINDO PHARMA LTD Marketing Status:  Prescription    This drug is: 

A provider is considering prescribing alosetron for a patien…

A provider is considering prescribing alosetron for a patient with severe IBS-D unresponsive to other treatments. Before initiating therapy, the provider must review the FDA Black Box Warning for this medication. Which serious risk must the provider discuss with the patient prior to prescribing?

Scenario: The patient suffered a right CVA 2 weeks ago. This…

Scenario: The patient suffered a right CVA 2 weeks ago. This patient is an otherwise healthy 70 year old male. Patient has left sided neglect with flaccid paralysis of left UE resulting in a subluxed shoulder and has some random movement of his left LE. List 2 different intervention techniques that should be used to address the left neglect?